BIOGEN INC (BIIB) Fundamental Analysis & Valuation

NASDAQ:BIIB • US09062X1037

Current stock price

187.06 USD
-2.22 (-1.17%)
At close:
187.17 USD
+0.11 (+0.06%)
After Hours:

This BIIB fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

7

1. BIIB Profitability Analysis

1.1 Basic Checks

  • In the past year BIIB was profitable.
  • BIIB had a positive operating cash flow in the past year.
  • In the past 5 years BIIB has always been profitable.
  • In the past 5 years BIIB always reported a positive cash flow from operatings.
BIIB Yearly Net Income VS EBIT VS OCF VS FCFBIIB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B

1.2 Ratios

  • BIIB has a Return On Assets of 4.39%. This is amongst the best in the industry. BIIB outperforms 90.50% of its industry peers.
  • BIIB's Return On Equity of 7.08% is amongst the best of the industry. BIIB outperforms 91.47% of its industry peers.
  • BIIB's Return On Invested Capital of 8.93% is amongst the best of the industry. BIIB outperforms 92.64% of its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for BIIB is significantly below the industry average of 28.06%.
  • The 3 year average ROIC (8.93%) for BIIB is below the current ROIC(8.93%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 4.39%
ROE 7.08%
ROIC 8.93%
ROA(3y)4.85%
ROA(5y)6.69%
ROE(3y)8.23%
ROE(5y)12.34%
ROIC(3y)8.93%
ROIC(5y)10.93%
BIIB Yearly ROA, ROE, ROICBIIB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10 20 30 40

1.3 Margins

  • BIIB has a Profit Margin of 13.07%. This is amongst the best in the industry. BIIB outperforms 92.05% of its industry peers.
  • BIIB's Profit Margin has declined in the last couple of years.
  • BIIB has a Operating Margin of 27.94%. This is amongst the best in the industry. BIIB outperforms 95.54% of its industry peers.
  • In the last couple of years the Operating Margin of BIIB has declined.
  • With an excellent Gross Margin value of 75.69%, BIIB belongs to the best of the industry, outperforming 82.36% of the companies in the same industry.
  • BIIB's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 27.94%
PM (TTM) 13.07%
GM 75.69%
OM growth 3Y-3.78%
OM growth 5Y-5.27%
PM growth 3Y-24.15%
PM growth 5Y-15.17%
GM growth 3Y-0.7%
GM growth 5Y-2.57%
BIIB Yearly Profit, Operating, Gross MarginsBIIB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. BIIB Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), BIIB is destroying value.
  • BIIB has more shares outstanding than it did 1 year ago.
  • BIIB has less shares outstanding than it did 5 years ago.
  • BIIB has a better debt/assets ratio than last year.
BIIB Yearly Shares OutstandingBIIB Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M
BIIB Yearly Total Debt VS Total AssetsBIIB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B 15B 20B 25B

2.2 Solvency

  • An Altman-Z score of 3.33 indicates that BIIB is not in any danger for bankruptcy at the moment.
  • BIIB has a Altman-Z score of 3.33. This is in the better half of the industry: BIIB outperforms 69.77% of its industry peers.
  • BIIB has a debt to FCF ratio of 3.11. This is a good value and a sign of high solvency as BIIB would need 3.11 years to pay back of all of its debts.
  • With an excellent Debt to FCF ratio value of 3.11, BIIB belongs to the best of the industry, outperforming 92.83% of the companies in the same industry.
  • BIIB has a Debt/Equity ratio of 0.34. This is a healthy value indicating a solid balance between debt and equity.
  • The Debt to Equity ratio of BIIB (0.34) is worse than 70.74% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.34
Debt/FCF 3.11
Altman-Z 3.33
ROIC/WACC0.97
WACC9.18%
BIIB Yearly LT Debt VS Equity VS FCFBIIB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B 15B

2.3 Liquidity

  • BIIB has a Current Ratio of 2.68. This indicates that BIIB is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 2.68, BIIB is doing worse than 67.44% of the companies in the same industry.
  • BIIB has a Quick Ratio of 2.03. This indicates that BIIB is financially healthy and has no problem in meeting its short term obligations.
  • BIIB has a worse Quick ratio (2.03) than 75.58% of its industry peers.
Industry RankSector Rank
Current Ratio 2.68
Quick Ratio 2.03
BIIB Yearly Current Assets VS Current LiabilitesBIIB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B 8B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. BIIB Growth Analysis

3.1 Past

  • BIIB shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 0.13%.
  • The earnings per share for BIIB have been decreasing by -14.17% on average. This is quite bad
  • Looking at the last year, BIIB shows a small growth in Revenue. The Revenue has grown by 2.22% in the last year.
  • BIIB shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -5.96% yearly.
EPS 1Y (TTM)0.13%
EPS 3Y-6.07%
EPS 5Y-14.17%
EPS Q2Q%18.21%
Revenue 1Y (TTM)2.22%
Revenue growth 3Y-0.93%
Revenue growth 5Y-5.96%
Sales Q2Q%1.93%

3.2 Future

  • BIIB is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 4.27% yearly.
  • The Revenue is expected to grow by 0.45% on average over the next years.
EPS Next Y5.45%
EPS Next 2Y3.4%
EPS Next 3Y3.98%
EPS Next 5Y4.27%
Revenue Next Year-3.54%
Revenue Next 2Y-1.96%
Revenue Next 3Y-0.91%
Revenue Next 5Y0.45%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
BIIB Yearly Revenue VS EstimatesBIIB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 5B 10B
BIIB Yearly EPS VS EstimatesBIIB Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 10 20 30

More info and screens

Find the best growth stocksShow best growing peers

7

4. BIIB Valuation Analysis

4.1 Price/Earnings Ratio

  • BIIB is valuated reasonably with a Price/Earnings ratio of 11.81.
  • Based on the Price/Earnings ratio, BIIB is valued cheaper than 96.71% of the companies in the same industry.
  • When comparing the Price/Earnings ratio of BIIB to the average of the S&P500 Index (26.64), we can say BIIB is valued rather cheaply.
  • A Price/Forward Earnings ratio of 11.44 indicates a reasonable valuation of BIIB.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of BIIB indicates a rather cheap valuation: BIIB is cheaper than 97.87% of the companies listed in the same industry.
  • The average S&P500 Price/Forward Earnings ratio is at 21.36. BIIB is valued slightly cheaper when compared to this.
Industry RankSector Rank
PE 11.81
Fwd PE 11.44
BIIB Price Earnings VS Forward Price EarningsBIIB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, BIIB is valued cheaply inside the industry as 97.09% of the companies are valued more expensively.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of BIIB indicates a rather cheap valuation: BIIB is cheaper than 97.29% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 13.6
EV/EBITDA 8.22
BIIB Per share dataBIIB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 20 40 60 80 100

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
  • BIIB has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)2.17
PEG (5Y)N/A
EPS Next 2Y3.4%
EPS Next 3Y3.98%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. BIIB Dividend Analysis

5.1 Amount

  • BIIB does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

BIIB Fundamentals: All Metrics, Ratios and Statistics

BIOGEN INC

NASDAQ:BIIB (5/1/2026, 8:11:36 PM)

After market: 187.17 +0.11 (+0.06%)

187.06

-2.22 (-1.17%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Industry Strength55.9
Industry Growth13.04
Earnings (Last)04-29
Earnings (Next)07-29
Inst Owners98.03%
Inst Owner Change0.26%
Ins Owners0.12%
Ins Owner Change7.89%
Market Cap27.45B
Revenue(TTM)9.89B
Net Income(TTM)1.29B
Analysts73.02
Price Target218.63 (16.88%)
Short Float %3.02%
Short Ratio3.99
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)21.18%
Min EPS beat(2)20.87%
Max EPS beat(2)21.48%
EPS beat(4)4
Avg EPS beat(4)24.64%
Min EPS beat(4)17.28%
Max EPS beat(4)38.92%
EPS beat(8)8
Avg EPS beat(8)17.2%
EPS beat(12)12
Avg EPS beat(12)12.76%
EPS beat(16)15
Avg EPS beat(16)12.81%
Revenue beat(2)2
Avg Revenue beat(2)3.75%
Min Revenue beat(2)1.26%
Max Revenue beat(2)6.23%
Revenue beat(4)4
Avg Revenue beat(4)6.45%
Min Revenue beat(4)1.26%
Max Revenue beat(4)11.62%
Revenue beat(8)6
Avg Revenue beat(8)2.98%
Revenue beat(12)9
Avg Revenue beat(12)2.26%
Revenue beat(16)11
Avg Revenue beat(16)1.92%
PT rev (1m)3.8%
PT rev (3m)13.13%
EPS NQ rev (1m)-1.35%
EPS NQ rev (3m)-14.83%
EPS NY rev (1m)0.27%
EPS NY rev (3m)4.37%
Revenue NQ rev (1m)0.31%
Revenue NQ rev (3m)-0.73%
Revenue NY rev (1m)-0.68%
Revenue NY rev (3m)1.6%
Valuation
Industry RankSector Rank
PE 11.81
Fwd PE 11.44
P/S 2.78
P/FCF 13.6
P/OCF 12.45
P/B 1.5
P/tB 10.61
EV/EBITDA 8.22
EPS(TTM)15.84
EY8.47%
EPS(NY)16.35
Fwd EY8.74%
FCF(TTM)13.76
FCFY7.36%
OCF(TTM)15.02
OCFY8.03%
SpS67.39
BVpS124.4
TBVpS17.63
PEG (NY)2.17
PEG (5Y)N/A
Graham Number210.561 (12.56%)
Profitability
Industry RankSector Rank
ROA 4.39%
ROE 7.08%
ROCE 10.59%
ROIC 8.93%
ROICexc 10.46%
ROICexgc 35.29%
OM 27.94%
PM (TTM) 13.07%
GM 75.69%
FCFM 20.42%
ROA(3y)4.85%
ROA(5y)6.69%
ROE(3y)8.23%
ROE(5y)12.34%
ROIC(3y)8.93%
ROIC(5y)10.93%
ROICexc(3y)9.96%
ROICexc(5y)13.03%
ROICexgc(3y)38.5%
ROICexgc(5y)36.85%
ROCE(3y)10.59%
ROCE(5y)12.95%
ROICexgc growth 3Y4.85%
ROICexgc growth 5Y-4.35%
ROICexc growth 3Y-13.95%
ROICexc growth 5Y-14.37%
OM growth 3Y-3.78%
OM growth 5Y-5.27%
PM growth 3Y-24.15%
PM growth 5Y-15.17%
GM growth 3Y-0.7%
GM growth 5Y-2.57%
F-Score4
Asset Turnover0.34
Health
Industry RankSector Rank
Debt/Equity 0.34
Debt/FCF 3.11
Debt/EBITDA 1.77
Cap/Depr 23.77%
Cap/Sales 1.87%
Interest Coverage 10.46
Cash Conversion 62.22%
Profit Quality 156.18%
Current Ratio 2.68
Quick Ratio 2.03
Altman-Z 3.33
F-Score4
WACC9.18%
ROIC/WACC0.97
Cap/Depr(3y)46.72%
Cap/Depr(5y)49.51%
Cap/Sales(3y)2.92%
Cap/Sales(5y)2.77%
Profit Quality(3y)138.91%
Profit Quality(5y)133.83%
High Growth Momentum
Growth
EPS 1Y (TTM)0.13%
EPS 3Y-6.07%
EPS 5Y-14.17%
EPS Q2Q%18.21%
EPS Next Y5.45%
EPS Next 2Y3.4%
EPS Next 3Y3.98%
EPS Next 5Y4.27%
Revenue 1Y (TTM)2.22%
Revenue growth 3Y-0.93%
Revenue growth 5Y-5.96%
Sales Q2Q%1.93%
Revenue Next Year-3.54%
Revenue Next 2Y-1.96%
Revenue Next 3Y-0.91%
Revenue Next 5Y0.45%
EBIT growth 1Y8.4%
EBIT growth 3Y-4.68%
EBIT growth 5Y-10.91%
EBIT Next Year17.07%
EBIT Next 3Y5.07%
EBIT Next 5Y1.28%
FCF growth 1Y-19.74%
FCF growth 3Y20.95%
FCF growth 5Y-11.3%
OCF growth 1Y-23.33%
OCF growth 3Y16.78%
OCF growth 5Y-12.22%

BIOGEN INC / BIIB Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for BIOGEN INC?

ChartMill assigns a fundamental rating of 5 / 10 to BIIB.


What is the valuation status of BIOGEN INC (BIIB) stock?

ChartMill assigns a valuation rating of 7 / 10 to BIOGEN INC (BIIB). This can be considered as Undervalued.


Can you provide the profitability details for BIOGEN INC?

BIOGEN INC (BIIB) has a profitability rating of 7 / 10.


What is the financial health of BIOGEN INC (BIIB) stock?

The financial health rating of BIOGEN INC (BIIB) is 6 / 10.


What is the earnings growth outlook for BIOGEN INC?

The Earnings per Share (EPS) of BIOGEN INC (BIIB) is expected to grow by 5.45% in the next year.